By Diagnostics World Staff
November 24, 2025 | Royal Philips extended their partnership with Cortechs.ai; OCEAN Dx completes a clinical evaluation study for its innovative rapid diagnostic test for sepsis; Nucleai and the University of Glasgow announce a collaboration; and more.
Royal Philips extended their partnership with Cortechs.ai. The companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems, empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration combines Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuro imaging post processing software to transform how neurological diseases are detected, monitored, and managed. Press release.
Zinzino has a personalized at-home test: the Gut Health Test, completed with a simple finger prick. This innovative approach reveals not only which microbes are present but also whether they are active, what they produce, and how the body responds to them. The result is a deeper understanding of the gut-body connection, how diet and lifestyle influence it, and how to support a healthier, more resilient body from the inside out. Press release.
ChristianaCare’s Cawley Center for Translational Cancer Research has unveiled a first-of-its-kind organoid core in a community cancer center program. The new laboratory facility within the Helen F. Graham Cancer Center & Research Institute grows and tests living, patient-derived tumor models, which give doctors and researchers a faster, more precise way to identify the therapies most likely to work for each patient. By growing living tumor models from cells of individual patients, researchers can test real-world drug responses and tailor treatments for them in new, innovative ways. Press release.
FUJIFILM Healthcare Americas Corporation launches Synapse One, a comprehensive, tailor-made workflow solution designed for unique outpatient imaging needs in North America. This all-inclusive enterprise imaging solution enables providers to address everything from patient engagement portal, self-scheduling of exams, Radiology Information System, advanced scheduling capability, Revenue Cycle Management options, Picture Archiving and Communication System, advanced 3D imaging, physician portal, and more, all within the Synapse platform in the secure Amazon Web Services cloud. Press release.
Molecular Designs launches its Human Papillomavirus (HPV) Simplicity Panel, a next-generation multiplex PCR-based Research Use Only panel designed to identify 14 high-risk HPV types. The HPV Simplicity Panel supports the research of high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The panel delivers same-day results with high analytical accuracy and reproducibility. The HPV Simplicity Panel aims to give research laboratories a streamlined tool to study high-risk HPV prevalence and its role in disease development. Press release.
OCEAN Dx completed a clinical evaluation study for its innovative rapid diagnostic test for sepsis. The study involved 107 patients and achieved results consistent with the gold standard for sepsis detection. This marks a milestone in OCEAN Dx’s mission to provide clinicians with fast and accurate diagnostic tools. This test can aid with improving patient triage, supporting treatment decisions, enhancing antibiotic management (including de-escalation), and helping to prevent antibiotic resistance. Press release.
New England Biolabs has released the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), designed to streamline and scale the sequencing of Influenza A virus from a range of species and sample types using Oxford Nanopore Technologies platforms. This launch marks a significant step forward in enabling rapid, high-throughput surveillance of seasonal and emerging flu subtypes (e.g., H3N2, H1N1, and H5N1). Press release.
Nucleai and the University of Glasgow are collaborating to identify and validate predictive biomarkers for colorectal cancer and advanced polyp incidence. The project leverages artificial intelligence and multimodal spatial biology data, combining tissue, molecular, and clinical data to improve patient risk stratification and early detection. The collaboration will analyze data from the Integrated Technologies for Improved Polyp Surveillance (INCISE) study—one of the world’s most comprehensive and unique colon precancerous polyp cohorts—to uncover how tissue architecture, cell-to-cell interactions, and molecular signaling influence cancer progression. These insights will help develop clinically validated precision diagnostic products, designed to predict disease risk, and personalize surveillance strategies. Press release.
Brainomix has joined the Innovators' Network at the American Heart Association Center for Health Technology & Innovation (the Center). The Innovators' Network is a consortium connecting entrepreneurs, providers, researchers, and payers to advance cardiovascular and brain health innovation. Members have the opportunity to access the association's digital evidence-based scientific guidelines and clinical recommendations as they develop digital healthcare technologies. Members collaborate with the center in different ways, including building models for clinical outcome studies, which lowers the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes. Press release.
Form Bio and Weill Cornell Medicine are collaborating to apply gene editing to develop drugs that reduce Alzheimer's disease risk in patients carrying high-risk genetic variants. This multi-phase initiative represents a significant step toward addressing one of the strongest genetic drivers of Alzheimer's disease. Carriers of the APOE4 allele face a substantially higher likelihood of developing Alzheimer's, making it a critical target for intervention. Press release.
Biostate AI has partnered with Narayana Health to develop the first AI models specifically designed to predict cardiovascular disease in Indian populations. The partnership tackles what clinicians call the "Data Gap," the fact that virtually all cardiovascular risk algorithms were developed using European and American patient data, despite South Asians developing heart disease 5-10 years earlier than Western populations and presenting with different genetic and molecular patterns. This leads to missed diagnoses, late-stage detection, and preventable deaths. Press release.
Inify Laboratories expanded its service offering during the third quarter with the addition of a second diagnostic area: gastroenterology. In September, the company launched gastrointestinal diagnostics services in Sweden and successfully diagnosed its first patient samples. The company plans to gradually introduce this area into the U.K. operations. Press release.